MCID: NDL009
MIFTS: 40

Nodular Basal Cell Carcinoma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Nodular Basal Cell Carcinoma

MalaCards integrated aliases for Nodular Basal Cell Carcinoma:

Name: Nodular Basal Cell Carcinoma 12 15
Skin Nodulo-Ulcerative Basal Cell Carcinoma 12
Circumscribed Solid Basal Cell Carcinoma 12
Skin Nodular Solid Basal Cell Carcinoma 71
Nodulo-Ulcerative Basal Cell Carcinoma 71
Skin Solid Basal Cell Carcinoma 12
Skin Nodular Basal Cell Carcinoma 71
Basal Cell Carcinoma, Nodular 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4280
NCIt 50 C62282
SNOMED-CT 67 716274007
UMLS 71 C0862887 C1304300 C1879347

Summaries for Nodular Basal Cell Carcinoma

Disease Ontology : 12 A basal cell carcinoma characterized by elevated, pearl shaped nodules with telengactisae on the surface and periphery.

MalaCards based summary : Nodular Basal Cell Carcinoma, also known as skin nodulo-ulcerative basal cell carcinoma, is related to basal cell carcinoma and superficial basal cell carcinoma. An important gene associated with Nodular Basal Cell Carcinoma is PRKX (Protein Kinase X-Linked), and among its related pathways/superpathways are Relaxin signaling pathway and Keratinization. The drugs Aminolevulinic acid and Imiquimod have been mentioned in the context of this disorder. Affiliated tissues include skin.

Related Diseases for Nodular Basal Cell Carcinoma

Graphical network of the top 20 diseases related to Nodular Basal Cell Carcinoma:



Diseases related to Nodular Basal Cell Carcinoma

Symptoms & Phenotypes for Nodular Basal Cell Carcinoma

Drugs & Therapeutics for Nodular Basal Cell Carcinoma

Drugs for Nodular Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 12)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 3 106-60-5 137
2
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
3 Methyl 5-aminolevulinate Phase 3
4 Dermatologic Agents Phase 3
5 Photosensitizing Agents Phase 3
6 Immunologic Factors Phase 3
7 Adjuvants, Immunologic Phase 3
8 interferons Phase 3
9 Anesthetics Phase 3
10
Fluorouracil Approved Phase 1, Phase 2 51-21-8 3385
11
Asparagine Approved, Investigational, Nutraceutical Phase 1, Phase 2 70-47-3 6267
12 Interferon-gamma Phase 1, Phase 2

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 A Randomized Open Label Study to Evaluate the Safety and Efficacy if Imiquimod 5% Cream Applied 3 Times Per Week for 8 or 12 Weeks in the Treatment of Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4 Imiquimod
2 Topical Imiquimod 5% Cream in the Treatment of Nodular Basal Cell Carcinoma After Initial Treatment With Curettage Completed NCT00314756 Phase 4 imiquimod
3 A Multicentre, Phase III, Double Blind Study of Photodynamic Therapy (PDT) With Metvix® 160 mg/g Cream in Comparison to PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma. Completed NCT00472043 Phase 3
4 A Multicenter, Phase III, Double Blind Study of Photodynamic Therapy (PDT) With Metvix 160 mg/g Cream in Comparison to PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma Completed NCT00472108 Phase 3
5 Surgical Excision Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma: an Open, Non-inferiority, Randomized Controlled Trial Active, not recruiting NCT02242929 Phase 3 Imiquimod 5% cream with prior curettage
6 A Phase 1/2a Study of the Efficacy and Safety of ASN-002 Alone or in Combination With 5-FU in Adult Patients With Low-risk Nodular Basal Cell Carcinoma Completed NCT02550678 Phase 1, Phase 2 5-FU
7 A Multi-center, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Nodular Basal Cell Carcinoma Completed NCT00108121 Phase 2 PEP005
8 Double-Blind, Dose Escalating, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas Completed NCT02828111 Phase 2 Patidegib;Vehicle gel
9 Bi-center, Open Label, Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC) Terminated NCT01808950 Phase 1, Phase 2 0.06% Resiquimod Gel - A;0.06% Resiquimod Gel - B;0.06% Resiquimod Gel - C
10 Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Nodular Basal Cell Carcinoma in Asian: A Prospective, Randomized Study With 12 Months Follow-up Completed NCT02018679 Phase 1
11 Randomized Pilot Study of Treatment for Basal Cell Carcinoma Using the Multiplex 595/1064 nm Laser Completed NCT02270645
12 A Randomized Controlled Blinded Multi-centre Study of Photodynamic Therapy With Methyl-aminolevulinate Comparing a Simplified Regime With the Approved Regime in Patients With Clinical Low-risk Superficial and Nodular Basal Cell Carcinoma. Completed NCT01482104 MAL-PDT re-treatment;usual MAL-PDT

Search NIH Clinical Center for Nodular Basal Cell Carcinoma

Genetic Tests for Nodular Basal Cell Carcinoma

Anatomical Context for Nodular Basal Cell Carcinoma

MalaCards organs/tissues related to Nodular Basal Cell Carcinoma:

40
Skin

Publications for Nodular Basal Cell Carcinoma

Articles related to Nodular Basal Cell Carcinoma:

(show top 50) (show all 202)
# Title Authors PMID Year
1
Treatment of cutaneous basal cell carcinoma with combined laser extirpation and methyl aminolevulinic acid: five-year success rates. 61
33557701 2021
2
Comparative histological and immunohistochemical changes in recurrent nodular basal cell carcinoma after photodynamic therapy. 61
33438310 2021
3
Comment on "Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma: One-year results of a noninferiority, randomized, controlled trial". 61
32860912 2021
4
Reply to: Comment on "Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma: One-year results of a noninferiority, randomized, controlled trial". 61
32861711 2021
5
Methyl aminolevulinate photodynamic therapy after partial debulking in the treatment of superficial and nodular basal cell carcinoma: 3-years follow-up. 61
33429099 2021
6
Topical Imiquimod as a Treatment Option for Nodular Basal Cell Carcinoma: A Systematic Review. 61
32527151 2020
7
Cytotoxic T-Lymphocyte-Associated Protein-4 and Lymphocyte Activation Gene-3 Expression in Orbitally-Invasive Versus Nodular Basal Cell Carcinoma. 61
32991494 2020
8
Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma: One-year results of a noninferiority, randomized, controlled trial. 61
32320773 2020
9
Adenoid Cystic Basal Cell Carcinoma Arising in Rhinophyma. 61
33304635 2020
10
Primary Conjunctival Pigmented Basal Cell Carcinoma with Increased Numbers of Intra-Tumour Melanocytes, Mimicking Melanoma: A Case Report and Review of the Literature. 61
32509761 2020
11
Use of dermograph for improvement of PpIX precursor's delivery in photodynamic therapy: Experimental and clinical pilot studies. 61
31731063 2020
12
Multispectral near infrared absorption imaging for histology of skin cancer. 61
31602799 2020
13
Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literature. 61
31361351 2020
14
Basal Cell Carcinoma Surgery in general practice: Is there a role for the local General Practitioner? 61
33329859 2020
15
[Young male patient with unusual space-occupying lesion of the lower eyelid]. 61
31359135 2020
16
European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications - actinic keratoses, Bowen's disease and basal cell carcinomas. 61
31779042 2019
17
Photodynamic therapy: A targeted literature review focussing on outcomes and optimisation in solid organ transplant recipients. 61
31012102 2019
18
Basal Cell Carcinoma Originating in a Tattoo: Case Report and Review of an Uncommon Complication in Tattoo Recipients. 61
31723458 2019
19
High-frequency ultrasound in the diagnosis of selected non-melanoma skin nodular lesions. 61
31839774 2019
20
Utilization of optical coherence tomography as a noninvasive, bedside imaging technique to identify residual nodular basal cell carcinoma at a well-healed and clinically unidentifiable biopsy site. 61
30771419 2019
21
Excision of nodular basal cell carcinoma involving the lower eyelid tarsal skin using a grey line-splitting, posterior lamella-sparing technique. 61
29461902 2019
22
Skin cancer incidence in rural workers at a reference hospital in western Paraná. 61
33261790 2019
23
Skin cancer incidence in rural workers at a reference hospital in western Paraná. 61
31090820 2019
24
Basal Cell Carcinoma Associated with Secondary Localized Cutaneous Amyloid Deposits: Case Report and Review. 61
30899630 2019
25
Dermoscopy Patterns and Histopathological Findings in Nodular Basal Cell Carcinoma-Study on 68 Cases. 61
31297272 2019
26
Ultrasonographic features of superficial and nodular basal cell carcinoma. 61
30534655 2018
27
A systematic review on the use of cryotherapy versus other treatments for basal cell carcinoma. 61
30695972 2018
28
Intradermal Delivery of a Near-Infrared Photosensitizer Using Dissolving Microneedle Arrays. 61
29864428 2018
29
Solitary plantar basal cell carcinoma. 61
29924227 2018
30
Solitary plantar basal cell carcinoma. 61
33288092 2018
31
Nodular basal cell carcinoma of the face successfully treated with ingenol mebutate 0.015% gel. 61
29785331 2018
32
Analysis of hedgehog signaling in periocular sebaceous carcinoma. 61
29423837 2018
33
Eyelid Reconstruction: Pediculated versus Non-Pediculated. 61
29351708 2018
34
Assessment of singlet oxygen dosimetry concepts in photodynamic therapy through computational modeling. 61
29292205 2018
35
An Experimental and Numerical Study on Nodular Gel Phantom during Cryotherapy. 61
29734423 2018
36
Programmed Death-1 Pathway in Orbital Invasion of Cutaneous Carcinomas. 61
28350690 2018
37
Macrophage subtypes in recurrent nodular basal cell carcinoma after Mohs micrographic surgery. 61
28994114 2017
38
Superiorly based nasolabial island flap for reconstruction of the lateral lower eyelid 61
29306222 2017
39
Dynamic thiol/disulphide homeostasis in patients with basal cell carcinoma. 61
28067074 2017
40
Injectable Diphenhydramine Used as Anaesthetic for Wide Local Excision With Flap Closure. 61
27920067 2017
41
Basal Cell Carcinoma Arising in a Breast Augmentation Scar. 61
28130559 2017
42
Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial. 61
27932240 2017
43
A rare dermoscopic pattern of nodular basal cell carcinoma with amyloid deposition. 61
28087032 2017
44
Auricular Hemosiderosis in a Diabetic Patient. 61
28859747 2017
45
Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area. 61
28300740 2017
46
A Multicenter Clinical Study of Expected and Unexpected Side Reactions During and After Skin Cancer Treatment by Photodynamic Therapy. 61
28528604 2017
47
Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis. 61
27363535 2016
48
A retrospective study on the effectiveness of curettage and electrodesiccation for clinically suspected primary nodular basal cell carcinoma. 61
27229620 2016
49
An Interesting Case of Basal Cell Carcinoma with Raynaud's Phenomenon Following Chronic Arsenic Exposure. 61
28029677 2016
50
Altered Expression of PRKX, WNT3 and WNT16 in Human Nodular Basal Cell Carcinoma. 61
27630294 2016

Variations for Nodular Basal Cell Carcinoma

Cosmic variations for Nodular Basal Cell Carcinoma:

9 (show top 50) (show all 3424)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM84510986 ZNF276 skin,NS,carcinoma,basal cell carcinoma c.*940C>T p.? 16:89739186-89739186 12
2 COSM149268805 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1261G>A p.G421R 16:72958885-72958885 12
3 COSM87274302 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1655C>T p.S552F 16:72958491-72958491 12
4 COSM87270496 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.10847C>T p.S3616F 16:72787429-72787429 12
5 COSM149259613 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.10847C>T p.S3616F 16:72787429-72787429 12
6 COSM149268792 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.5825G>A p.G1942E 16:72796857-72796857 12
7 COSM87274307 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1261G>A p.G421R 16:72958885-72958885 12
8 COSM149268800 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1655C>T p.S552F 16:72958491-72958491 12
9 COSM87273325 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.2084C>T p.P695L 16:72958062-72958062 12
10 COSM149304906 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1991C>T p.S664F 16:72958155-72958155 12
11 COSM87296537 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.11050G>A p.D3684N 16:72787226-72787226 12
12 COSM102023150 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7526C>T p.? 16:72958491-72958491 12
13 COSM102023155 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7920G>A p.? 16:72958885-72958885 12
14 COSM102019420 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.8105C>T p.S2702F 16:72787429-72787429 12
15 COSM149331772 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.11050G>A p.D3684N 16:72787226-72787226 12
16 COSM102023144 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.3083G>A p.G1028E 16:72796857-72796857 12
17 COSM102047764 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.8308G>A p.D2770N 16:72787226-72787226 12
18 COSM87286441 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1991C>T p.S664F 16:72958155-72958155 12
19 COSM102036925 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7190C>T p.? 16:72958155-72958155 12
20 COSM149266372 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.2084C>T p.P695L 16:72958062-72958062 12
21 COSM102022243 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7097C>T p.? 16:72958062-72958062 12
22 COSM87274293 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.5825G>A p.G1942E 16:72796857-72796857 12
23 COSM104882801 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 12
24 COSM104236272 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 12
25 COSM101976974 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 12
26 COSM87040659 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 12
27 COSM101179498 TSC2 skin,NS,carcinoma,basal cell carcinoma c.1913C>T p.S638F 16:2071897-2071897 12
28 COSM150324396 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 12
29 COSM101191558 TSC2 skin,NS,carcinoma,basal cell carcinoma c.722C>T p.P241L 16:2058767-2058767 12
30 COSM147706701 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 12
31 COSM150353664 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 12
32 COSM151748023 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 12
33 COSM150576157 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 12
34 COSM149802478 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 12
35 COSM148980439 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 12
36 COSM90415129 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 12
37 COSM149800636 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 12
38 COSM148991757 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 12
39 COSM151513825 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 12
40 COSM151753165 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 12
41 COSM151371066 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 12
42 COSM136628294 TSC2 skin,NS,carcinoma,basal cell carcinoma c.902C>T p.P301L 16:2058767-2058767 12
43 COSM110103971 TSC2 skin,NS,carcinoma,basal cell carcinoma c.568T>A p.C190S 16:2056674-2056674 12
44 COSM150583851 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 12
45 COSM102616914 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 12
46 COSM136618116 TSC2 skin,NS,carcinoma,basal cell carcinoma c.712T>A p.C238S 16:2056674-2056674 12
47 COSM110102044 TSC2 skin,NS,carcinoma,basal cell carcinoma c.1949C>T p.S650F 16:2071897-2071897 12
48 COSM150574866 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 12
49 COSM102629996 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 12
50 COSM148982237 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 12

Expression for Nodular Basal Cell Carcinoma

Search GEO for disease gene expression data for Nodular Basal Cell Carcinoma.

Pathways for Nodular Basal Cell Carcinoma

Pathways related to Nodular Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.05 KRT38 KRT35 KRT31 KRT15
2
Show member pathways
11.71 KRT38 KRT35 KRT31 KRT15
3
Show member pathways
11 WNT3 WNT16
4 10.91 KRT38 KRT35 KRT31 KRT15

GO Terms for Nodular Basal Cell Carcinoma

Cellular components related to Nodular Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.43 WNT3 TOM1L1 KRT38 KRT35 KRT31 KRT15
2 intermediate filament GO:0005882 9.02 KRT38 KRT35 KRT31 KRT15 BFSP1

Biological processes related to Nodular Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell fate commitment GO:0045165 9.32 WNT3 WNT16
2 canonical Wnt signaling pathway GO:0060070 9.26 WNT3 WNT16
3 keratinization GO:0031424 9.26 KRT38 KRT35 KRT31 KRT15
4 hyaluronan catabolic process GO:0030214 9.16 HYAL3 HMMR
5 cornification GO:0070268 8.92 KRT38 KRT35 KRT31 KRT15

Molecular functions related to Nodular Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 frizzled binding GO:0005109 9.16 WNT3 WNT16
2 structural constituent of cytoskeleton GO:0005200 9.13 KRT31 KRT15 BFSP1
3 structural molecule activity GO:0005198 8.92 KRT38 KRT35 KRT31 KRT15

Sources for Nodular Basal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....